A perturbation problem arising from the modelling of soluble fas ligand in tumour immunology

Mathematical and Computer Modelling

Volumn 37, Issue 3-4, 2003, Pages 323-331

  Webb, S D ^a   Sherratt, J A ^b  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

Fas FasL; Immunology; Modelling; Singular perturbation

Indexed keywords

EID: 0037372903     PISSN: 08957177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7177(03)00009-8     Document Type: Article

References (14)

1. S. Chouaib, C. Asselin-Paturel, F. Mami Chouaib, A. Caignard and J.Y. Blay, The host-tumour immune conflict: From immunosuppression to resistance and destruction, Immunol. Today 18, 493-497 (1997).
2. J. O'Connell, M.W. Bennett, G.C. O'Sullivan, J.K. Collins and F. Shanahan. The Fas counterattack: Cancer as a site of immune privilege, Immunol. Today 20, 46-52 (1999).
3. P.R. Walker, P. Saas and P.Y. Dietrich, Tumour expression of Fas ligand (CD95L) and the consequences, Curr. Op. Immunol. 10, 564-572 (1998).
4. T.A. Ferguson and T.S. Griffiths, A vision of cell death: Insights into immune privilege, Immunol. Rev. 156, 167-184 (1997).
5. C.C. Liu, L.H.Y. Young and J.D.E. Young, Lymphocyte-mediated cytolysis and disease, New Eng. J. Med. 335, 1651-1659 (1996).
6. D.H. Lynch, F. Ramsdell and M.R. Alderson, Fas and Fas-L in the homeostatic regulation of immune responses, Immunol. Today 16, 569-574 (1995).
7. K. Shiraki, N. Tsaji, N. Shioda, K.J. Isselbacker and H. Takahashi, Expression of Fas ligand in liver metastases of human colonic adenocarcinomas, Proc. Natl. Acad. Sci. 94, 6420-6425 (1997).
8. C. Gratas, Y. Tohma, C.B. Barnes, P. Taniere, P. Hainaut and H. Ohgaki, Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer, Cancer Res. 58, 2057-2062 (1998).
9. A. Zeytun, M. Hassunch, M. Nagarkatti and P.S. Nagarkatti, Fas-Fas ligand-based interactions between tumour cells and tumour specific cytotoxic T lymphocytes: A lethal two-way street, Blood 90, 1952-1959 (1997)
10. S.D. Webb, J.A. Sherratt and R.G. Fish, Cells behaving badly: A theoretical model for the Fas/FasL system in tumour Immunology, Math. Biosci. 179, 113-129 (2002).
11. R. Watanabe-Fukunaga, C.I. Brannan, N. Itoh, S. Yonehara, N.G. Copeland, N.A. Jenkins and S. Nagata, The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen, J. Immunol. 148, 1274-1279 (1992).
12. D.A. Lauffenburger and J.J. Linderman, Receptors: Models for Binding, Trafficking, and Signalling, Oxford University Press, (1993).
13. M. Tanaka, T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ogha, K. Hatake, A.H. Drummond and S. Nagata, Fas ligand in human serum, Nat. Med. 2, 317-322 (1996).
14. G.P. Midas, Y. Shen and L.B. Owen-Schaub, Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy, Cancer Res. 56, 3370-3874 (1996).